• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

终末期肾病中巨细胞病毒感染的流行病学

Epidemiology of cytomegalovirus infection in end stage renal disease.

作者信息

Betts R F, Cestero R V, Freeman R B, Douglas R G

出版信息

J Med Virol. 1979;4(2):89-96. doi: 10.1002/jmv.1890040203.

DOI:10.1002/jmv.1890040203
PMID:226657
Abstract

Since primary cytomegalovirus (CMV) infection is a cause of morbidity among renal transplant recipients, we undertook a prospective study of our maintenance hemodialysis patients and personnel to determine whether these sources posed a risk for transmission of CMV. Our study of 85 patients and 49 personnel showed that CMV was detected in eight nontransplanted, older dialysis patients and 13 patients who had lost their allograft. In spite of the presence of CMV on the unit, no patient or staff member developed primary infection from interpersonal transmission or from transfused frozen red blood cells. All primary infections in renal transplant patients could be accounted for by acquisition from the transplanted kidney, thus eliminating the dialysis unit or frozen blood as a risk to either patients or personnel.

摘要

由于原发性巨细胞病毒(CMV)感染是肾移植受者发病的一个原因,我们对维持性血液透析患者及工作人员进行了一项前瞻性研究,以确定这些传染源是否构成CMV传播风险。我们对85例患者和49名工作人员的研究表明,在8例未接受移植的老年透析患者和13例移植肾失功的患者中检测到了CMV。尽管透析单元存在CMV,但没有患者或工作人员因人际传播或输注冷冻红细胞而发生原发性感染。肾移植患者的所有原发性感染都可归因于从移植肾获得,因此排除了透析单元或冷冻血液对患者或工作人员的风险。

相似文献

1
Epidemiology of cytomegalovirus infection in end stage renal disease.终末期肾病中巨细胞病毒感染的流行病学
J Med Virol. 1979;4(2):89-96. doi: 10.1002/jmv.1890040203.
2
Cytomegalovirus infection and immunity in renal allograft recipients: assessment of the competence of humoral immunity.肾移植受者的巨细胞病毒感染与免疫:体液免疫能力评估
Infect Immun. 1976 Jun;13(6):1633-7. doi: 10.1128/iai.13.6.1633-1637.1976.
3
Cytomegalovirus infection in dialysis patients and personnel.透析患者及工作人员中的巨细胞病毒感染
Ann Intern Med. 1978 Nov;89(5 Pt 1):625-8. doi: 10.7326/0003-4819-89-5-625.
4
CMV infection in patients with chronic renal failure and in those following transplantation.
Czech Med. 1988;11(3):131-6.
5
Prevention of CMV infection by screening for CMV antibodies in renal allograft recipients and their blood and kidney donors.通过筛查肾移植受者及其血液和肾脏供体中的巨细胞病毒抗体来预防巨细胞病毒感染。
Scand J Infect Dis. 1988;20(2):135-9. doi: 10.3109/00365548809032429.
6
Cytomegalovirus disease in a renal transplant recipient: the importance of pre-transplant screening of the donor and recipient.肾移植受者的巨细胞病毒病:供体和受体移植前筛查的重要性
Saudi J Kidney Dis Transpl. 2013 Jan;24(1):80-5. doi: 10.4103/1319-2442.106250.
7
Cytomegalovirus infection and kidney graft survival.
Scand J Urol Nephrol Suppl. 1981;64:128-31.
8
Clinical manifestations of renal allograft derived primary cytomegalovirus infection.肾移植受者原发性巨细胞病毒感染的临床表现。
Am J Dis Child. 1977 Jul;131(7):759-63. doi: 10.1001/archpedi.1977.02120200041010.
9
Pretransplant recipient cytomegalovirus seropositivity and hemodialysis are associated with decreased renal allograft and patient survival.移植前受者巨细胞病毒血清学阳性和血液透析与肾移植受者生存率及移植肾存活率降低相关。
Transplantation. 2004 May 15;77(9):1405-11. doi: 10.1097/01.tp.0000122184.97674.20.
10
CMV mismatch does not affect patient and graft survival in UK renal transplant recipients.巨细胞病毒错配不影响英国肾移植受者的患者及移植物存活率。
Transplantation. 2009 Jul 15;88(1):77-82. doi: 10.1097/TP.0b013e3181aa8d36.

引用本文的文献

1
Unusual nosocomial infections.罕见的医院感染。
Dis Mon. 1984 Oct;30(13):1-68. doi: 10.1016/0011-5029(84)90018-x.
2
Polypeptides and major antigens of four new isolates of cytomegalovirus.四种巨细胞病毒新分离株的多肽和主要抗原
Med Microbiol Immunol. 1981;169(3):197-208. doi: 10.1007/BF02123593.
3
Acquisition of cytomegalovirus infection: an update.巨细胞病毒感染的获得:最新进展
Clin Microbiol Rev. 1989 Apr;2(2):204-16. doi: 10.1128/CMR.2.2.204.